| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2012.44.3762 |
| P698 | PubMed publication ID | 23715562 |
| P50 | author | Alexander Eggermont | Q28317101 |
| Stefan Suciu | Q99568574 | ||
| Wim H J Kruit | Q130288623 | ||
| P2093 | author name string | Johan Vansteenkiste | |
| Bart Spiessens | |||
| Benjamin Dizier | |||
| Fernando Ulloa-Montoya | |||
| Jamila Louahed | |||
| Frédéric F Lehmann | |||
| Vincent G Brichard | |||
| Olivier Gruselle | |||
| P2860 | cites work | Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling | Q27860529 |
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 2388-2395 | |
| P577 | publication date | 2013-05-28 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. | |
| P478 | volume | 31 |
| Q64122484 | A Leukocyte Infiltration Score Defined by a Gene Signature Predicts Melanoma Patient Prognosis |
| Q101166208 | A balance score between immune stimulatory and suppressive microenvironments identifies mediators of tumour immunity and predicts pan-cancer survival |
| Q38903238 | A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification. |
| Q52562762 | APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer. |
| Q34563201 | Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer |
| Q38831491 | Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward? |
| Q35200745 | Adjuvant chemotherapy in patients with completely resected non-small cell lung cancer |
| Q38555842 | Adjuvant therapy for high-risk melanoma |
| Q34031225 | Advances in adjuvant systemic therapy for non-small-cell lung cancer |
| Q38574574 | Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations |
| Q38390089 | Anti-tumor immune response in early stage non small cell lung cancer (NSCLC): implications for adjuvant therapy |
| Q90893993 | Approaches to treat immune hot, altered and cold tumours with combination immunotherapies |
| Q38554476 | Belagenpumatucel-L for the treatment of non-small cell lung cancer |
| Q47101079 | Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer |
| Q64988420 | Biomarkers in melanoma: where are we now? |
| Q33862861 | Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer |
| Q52385841 | Bringing the next Generation of Immuno-Oncology Biomarkers to the Clinic. |
| Q45931583 | CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. |
| Q37279217 | CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. |
| Q49592929 | Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment. |
| Q38151738 | Cancer immunotherapy: accomplishments to date and future promise |
| Q26769757 | Cancer stem cells and immunoresistance: clinical implications and solutions |
| Q49566680 | Cancer transcriptome profiling at the juncture of clinical translation |
| Q35770643 | Cancer-Testis Antigen Expression in Serous Endometrial Cancer with Loss of X Chromosome Inactivation |
| Q26745442 | Checkpoint Inhibitors and Their Application in Breast Cancer |
| Q50953528 | Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma. |
| Q26799117 | Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment |
| Q34338284 | Copy number loss of the interferon gene cluster in melanomas is linked to reduced T cell infiltrate and poor patient prognosis |
| Q38560048 | Current methods of epitope identification for cancer vaccine design |
| Q35154214 | Current status of autologous breast tumor cell-based vaccines |
| Q56897036 | Cutaneous melanoma |
| Q38791826 | Cutting Edge: Engineering Active IKKβ in T Cells Drives Tumor Rejection |
| Q45071748 | Differential Expression of Homing Receptor Ligands on Tumor-Associated Vasculature that Control CD8 Effector T-cell Entry. |
| Q36814030 | Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. |
| Q33750137 | Direct T cell-tumour interaction triggers TH1 phenotype activation through the modification of the mesenchymal stromal cells transcriptional programme |
| Q40626645 | Dysfunction of PSA-specific CD8+ T cells in prostate cancer patients correlates with CD38 and Tim-3 expression |
| Q40692551 | Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial |
| Q38232855 | Evolving role of tumor antigens for future melanoma therapies. |
| Q33599094 | Expression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer |
| Q38819729 | FAM26F: An Enigmatic Protein Having a Complex Role in the Immune System |
| Q45952214 | From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely. |
| Q48229380 | Futility for subgroup analyses in the adaptive signature design. |
| Q36051184 | Gene expression meta-analysis reveals immune response convergence on the IFNγ-STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphoma |
| Q39005203 | Gene-expression profiling to predict responsiveness to immunotherapy |
| Q38186704 | Genetic alterations and personalized medicine in melanoma: progress and future prospects |
| Q42380545 | Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. |
| Q38806243 | Harnessing the immune system for the treatment of melanoma: current status and future prospects. |
| Q92017713 | High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer |
| Q40675001 | High-resolution melting combines with Bayes discriminant analysis: a novel hepatitis C virus genotyping method |
| Q36110300 | High-throughput monitoring of human tumor-specific T-cell responses with large peptide pools |
| Q92073013 | IBI: Identification of Biomarker Genes in Individual Tumor Samples |
| Q93054534 | Identification of Distinct Immune Subtypes in Colorectal Cancer Based on the Stromal Compartment |
| Q33788685 | Identification of an immunogenic neo-epitope encoded by mouse sarcoma using CXCR3 ligand mRNAs as sensors |
| Q39175273 | Identification of biomarker-by-treatment interactions in randomized clinical trials with survival outcomes and high-dimensional spaces. |
| Q38875037 | Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. |
| Q39313889 | Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy |
| Q47195254 | Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity |
| Q38262757 | Immune biomarkers: how well do they serve prognosis in human cancers? |
| Q60375472 | Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms |
| Q38587157 | Immunotherapies for bladder cancer: a new hope. |
| Q38286376 | Immunotherapy and lung cancer: current developments and novel targeted therapies |
| Q100425508 | Immunotherapy for Localized Prostate Cancer: The Next Frontier? |
| Q38265555 | Immunotherapy for Lung Cancer: Has it Finally Arrived? |
| Q28083980 | Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms |
| Q38154289 | Immunotherapy for lung cancer: ongoing clinical trials |
| Q38259571 | Immunotherapy for non-small cell lung cancer. |
| Q38514566 | Immunotherapy for non-small-cell lung cancer: the past 10 years |
| Q38390093 | Immunotherapy in lung cancer |
| Q51132444 | Immunotherapy in lung cancer. |
| Q54978827 | Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages? |
| Q28078539 | Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites? |
| Q35506764 | In vivo profiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma |
| Q38716487 | Inhibition of tumor growth and metastasis by EMMPRIN multiple antigenic peptide (MAP) vaccination is mediated by immune modulation. |
| Q48267403 | Integrative clinical genomics of metastatic cancer |
| Q36925103 | Interferon-γ and Tumor Necrosis Factor-α Polarize Bone Marrow Stromal Cells Uniformly to a Th1 Phenotype |
| Q38398206 | Interferons and the Immunogenic Effects of Cancer Therapy |
| Q34476337 | Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? |
| Q28387769 | Lung Cancer Gene Signatures and Clinical Perspectives |
| Q64124167 | MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial |
| Q42908403 | MAGE-A3-specific anticancer immunotherapy in the clinical practice |
| Q38534721 | MAGE-A3: an immunogenic target used in clinical practice |
| Q50089395 | Mechanisms regulating T-cell infiltration and activity in solid tumors |
| Q38181180 | Melanoma-associated antigen-A3 vaccination in the treatment of non-small-cell lung cancer |
| Q38448175 | Model-based genotype-phenotype mapping used to investigate gene signatures of immune sensitivity and resistance in melanoma micrometastasis |
| Q47563785 | Module Analysis Captures Pancancer Genetically and Epigenetically Deregulated Cancer Driver Genes for Smoking and Antiviral Response. |
| Q28080773 | Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer |
| Q37148418 | Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients |
| Q33688872 | Molecular pathways and therapeutic targets in lung cancer |
| Q35828560 | Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy. |
| Q90468261 | Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer |
| Q52871134 | New Approaches in Immunotherapy for the Treatment of Lung Cancer. |
| Q99550699 | New biomarkers for checkpoint inhibitor therapy |
| Q38397279 | New clinical advances in immunotherapy for the treatment of solid tumours. |
| Q35300077 | New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape |
| Q37320156 | Next Generation Vaccine Biomarkers workshop October 30-31, 2014--Ottawa, Canada |
| Q38195656 | Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma. |
| Q26769884 | Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential |
| Q99711740 | Novel combination therapy for melanoma induces apoptosis via a gap junction positive feedback mechanism |
| Q26770780 | Novel technologies and emerging biomarkers for personalized cancer immunotherapy |
| Q38547040 | Personalized cancer immunotherapy using Systems Medicine approaches |
| Q28542859 | Pharmacogenomic approach to identify drug sensitivity in small-cell lung cancer |
| Q38416306 | Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy |
| Q40430036 | Pre-infection transcript levels of FAM26F in peripheral blood mononuclear cells inform about overall plasma viral load in acute and post-acute phase after simian immunodeficiency virus infection |
| Q27001126 | Primer on tumor immunology and cancer immunotherapy |
| Q38653619 | Prognostic and predictive biomarkers in melanoma: an update |
| Q37281267 | Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT). |
| Q48251012 | RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells |
| Q38826419 | Recent developments in the use of immunotherapy in non-small cell lung cancer |
| Q38149916 | Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions |
| Q93172097 | Role of cytokines in combinatorial immunotherapeutics of non-small cell lung cancer through systems perspective |
| Q49609103 | STING, DCs and the link between innate and adaptive tumor immunity. |
| Q39389951 | STING-mediated DNA sensing in cancer immunotherapy |
| Q55025685 | Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature. |
| Q42645831 | Single-cell mass cytometry and transcriptome profiling reveal the impact of graphene on human immune cells. |
| Q41976096 | Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein |
| Q40240112 | Sustained complete response to CTLA-4 blockade in a patient with metastatic, castration-resistant prostate cancer |
| Q37713498 | Systematic evaluation of immune regulation and modulation |
| Q36534662 | Systematic identification of genes with a cancer-testis expression pattern in 19 cancer types |
| Q38200798 | Targeted therapies in urothelial carcinoma. |
| Q58694964 | Targeting Chemokines and Chemokine Receptors in Melanoma and Other Cancers |
| Q39267252 | Testing interaction between treatment and high-dimensional covariates in randomized clinical trials. |
| Q64120761 | The Ins and Outs of Chemokine-Mediated Immune Cell Trafficking in Skin Cancer |
| Q27008371 | The STING pathway and the T cell-inflamed tumor microenvironment |
| Q37042237 | The host STING pathway at the interface of cancer and immunity |
| Q38691172 | The immune system and cancer evasion strategies: therapeutic concepts |
| Q35847321 | The immune-related role of BRAF in melanoma |
| Q57790346 | The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer |
| Q38506857 | The path forward |
| Q28397609 | Therapeutic cancer vaccines and combination immunotherapies involving vaccination |
| Q38162261 | Therapeutic cancer vaccines: a long and winding road to success |
| Q38227030 | Therapeutic vaccines for cancer: an overview of clinical trials |
| Q42734544 | Trial Watch: Peptide vaccines in cancer therapy |
| Q33878578 | Trial Watch: Toll-like receptor agonists in oncological indications |
| Q47678837 | Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma. |
| Q58567735 | Tumor mutational burden is a determinant of immune-mediated survival in breast cancer |
| Q34120040 | Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants |
| Q99408317 | Unveiling the Physical and Functional Niches of FAM26F by Analyzing Its Subcellular Localization and Novel Interacting Partners |
| Q26796314 | Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges |
| Q90733181 | WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment |
| Q85281790 | We are all individuals... bioinformatics in the personalized medicine era |
| Q55441788 | [Advances in immunotherapies for non-small cell lung cancer]. |
Search more.